Paul Varki's most recent trade in Avalo Therapeutics Inc was a trade of 1,081 Common Stock done at an average price of $13.1 . Disclosure was reported to the exchange on June 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.10 per share. | 10 Jun 2026 | 1,081 | 32,576 | - | 13.1 | 14,161 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 24,300 | 27,934 | - | 0 | Common Stock | |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.43 per share. | 06 May 2026 | 62,500 | 66,134 | - | 13.4 | 839,375 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2026 | 62,500 | 87,500 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 18.91 per share. | 06 May 2026 | 37,375 | 41,322 | - | 18.9 | 706,836 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.22 per share. | 06 May 2026 | 22,839 | 13,287 | - | 21.2 | 484,541 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2026 | 12,563 | 87,437 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 06 May 2026 | 12,563 | 78,697 | - | 8.0 | 101,007 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 22.70 per share. | 06 May 2026 | 9,253 | 4,034 | - | 22.7 | 210,029 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 19.78 per share. | 06 May 2026 | 5,196 | 36,126 | - | 19.8 | 102,783 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.71 per share. | 06 May 2026 | 400 | 3,634 | - | 23.7 | 9,484 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 1,016 | 3,634 | - | 4.1 | 4,166 | Common Stock |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Paul Varki | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) |